Socinski, M. A., Rittmeyer, A., Shapovalov, D., Orlandi, F., McCleod, M., Soo, R. A., Palmero, R., Kozuki, T., Migliorino, M. R., Koynov, K. D., Berard, H., Hughes, B. G. M., Yu, W., Graupner, V., Sun, S. W., Kowanetz, M., Hoang, T., Lin, W., & Jotte, R. M. (n.d.). lBA65IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095322315.0x00003c